Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT
Status:
Completed
Trial end date:
2019-11-12
Target enrollment:
Participant gender:
Summary
This study is a randomized, single-blind, placebo-controlled study to assess the efficacy and
safety of ciraparantag administered to healthy volunteers anticoagulated with rivaroxaban
measuring clotting times using Whole Blood Clotting Time (WBCT).
Phase:
Phase 2
Details
Lead Sponsor:
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. Perosphere, Inc.